Greenyn Biotechnology Co., Ltd. (6846) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Greenyn Biotechnology Co., Ltd. (6846:TWSE), powered by AI.

Current Price
$67.30
Sector
Healthcare
What is the Greenyn Biotechnology Co., Ltd. stock price forecast?

Greenyn Biotechnology Co., Ltd. is currently trading at $67.30. View real-time AI analysis on Alpha Lenz.

What is Greenyn Biotechnology Co., Ltd. insider trading activity?

View the latest insider trading data for Greenyn Biotechnology Co., Ltd. on Alpha Lenz.

What is Greenyn Biotechnology Co., Ltd.'s P/E ratio?

View Greenyn Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.

Greenyn Biotechnology Co., Ltd.

TWSE · 6846
NT$67.30+0.00(+0.00%)
Ask about Greenyn Biotechnology Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Greenyn Biotechnology Co., Ltd.'s ROE is 15.9%. Explore profitability and growth together.

Ask for details

Company Overview

Greenyn Biotechnology Co., Ltd. is a biotechnology company specializing in the research, development, manufacturing, and sale of health food raw materials and dietary supplements. Established in 2012 and headquartered in Taichung, Taiwan, the company focuses on innovative functional ingredients such as solid-state antrodia cinnamomea mycelia, bitter gourd peptide, and a comprehensive vegetable and fruit fermentation broth. Its proprietary product lines, including branded ingredients like Insumate, Antromax, and Zymologist 101, serve a diverse range of health needs, encompassing metabolic health, digestive support, immunity, youth and beauty, and specialized formulations for various life stages and health concerns. Greenyn’s portfolio features a wide array of functional formulas targeting digestion, brain health, energy, circulation, immune modulation, and more, making it a notable supplier to both domestic and international markets. The company is recognized for its R&D achievements, such as award-winning patented plant extracts, and plays a vital role in supporting the health technology and biotechnology sectors through extensive OEM/ODM services and global partnerships.

SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$915.32MRevenue
0.00Shares Out
0Employees

Margins

48.07%Gross
25.41%EBITDA
20.63%Operating
20.21%Pre-Tax
15.90%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

9.08%Rev 3Yr
6.68%Rev 5Yr
4.24%Op Inc 3Yr
3.41%Op Inc 5Yr
-0.28%Net Inc 3Yr
3.33%Net Inc 5Yr

Returns

9.04%ROA
15.90%ROE
12.24%ROIC

Financial Health

NT$793.36MCash & Cash Equivalents
NT$337.49MNet Debt
115.56%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Greenyn Biotechnology Co., Ltd. (ticker: 6846) is a company listed on TWSE in the Healthcare sector (Biotechnology).

The current price is 67.3 with a P/E ratio of -x and P/B of -x.

ROE is 15.90% and operating margin is 20.63%. Annual revenue is $915M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Greenyn Biotechnology Co., Ltd. (6846) Stock Forecast 2026 $67.30 — Price, Financials & Analyst Targets | Alpha Lenz